Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Malignant pleural mesothelioma

Oncology and palliative care · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Respiratory compromise or acute pleural complication

Severe hypoxaemia, tension physiology, empyema, major procedure-related bleeding, rapidly recurrent fluid or pulmonary embolism may complicate mesothelioma and pleural intervention.

Action: Use ABCDE assessment and urgent thoracic imaging, drain air, blood, infected or pressure-producing fluid through the appropriate respiratory or surgical pathway and treat sepsis or thrombosis without waiting for elective mesothelioma staging.

Synopsis

Recognise asbestos-related pleural malignancy, obtain adequate image-guided or thoracoscopic tissue, control recurrent effusion and pain and coordinate systemic, local, occupational and palliative care.

  • Malignant pleural mesothelioma is a diffuse pleural cancer strongly linked to asbestos exposure after a latency often exceeding several decades.
  • Key features are progressive unilateral chest pain, breathlessness, recurrent unilateral exudative effusion, pleural nodularity or rind and loss of hemithoracic volume.
  • Take a detailed lifetime exposure history including job tasks, employers, dates, work clothing, home renovation and para-occupational contact; smoking does not cause mesothelioma.
  • First-line imaging is contrast-enhanced CT thorax with pleural protocol and upper-abdominal coverage; ultrasound guides fluid and pleural sampling.
  • Histological core or thoracoscopic pleural biopsy is the diagnostic reference when the patient can tolerate it; do not rely on negative or equivocal cytology alone.
  • For recurrent symptomatic effusion, choose talc pleurodesis when lung expands or an indwelling pleural catheter when trapped lung, preference or outpatient control favours it.
  • Systemic treatment is selected from platinum-pemetrexed and current immunotherapy options by histology, performance, comorbidity and NICE eligibility; radical surgery is not routine.
  • Offer early specialist pain and palliative care and discuss occupational documentation, compensation and benefit routes without making legal support a substitute for clinical treatment.

Key red flags

Progressive unilateral chest pain and breathlessness with a recurrent unilateral pleural effusion or diffuse pleural thickening requires urgent pleural investigation.

A history of construction, shipyard, insulation, boiler, railway, military, factory or secondary household asbestos exposure matters even decades later.

Severe breathlessness or mediastinal shift after a pleural procedure raises pneumothorax, haemothorax or re-expansion complication.

Fever, purulent drainage, pleuritic pain or sepsis with an indwelling pleural catheter suggests pleural infection.

New leg swelling, pleuritic pain, syncope or unexplained oxygen requirement raises cancer-associated venous thromboembolism.

Procedure complication

Acute hypoxaemia, severe pain, bleeding or sepsis after biopsy, drain or catheter requires urgent pleural and surgical assessment.

Investigation priorities

01
First-line contrast CT thorax and upper abdomenFirst stepFirst line

Characterise pleural tumour, fluid, lung, nodes and invasion and identify a safe biopsy site.

Management branches

DiagnoseObtain pleural tissue safely

CT and clinical features suggest mesothelioma.

  1. Take a lifetime task-based asbestos history, assess performance and goals and review contrast CT with the pleural MDT.
  2. Drain only the amount needed for symptoms and diagnosis while planning image-guided core or thoracoscopy that will provide adequate tissue and stage information.
  3. Classify epithelioid, sarcomatoid or biphasic disease with specialist pathology and complete only the staging tests capable of changing treatment.

Key medicines

Pemetrexed with platinumGive pemetrexed 500 mg/m² intravenously on day 1 of each 21-day cycle with cisplatin 75 mg/m² or protocol-selected carboplatin, using the current mesothelioma regimen and organ-function criteria.Give folic acid and vitamin B12 supplementation and dexamethasone skin prophylaxis exactly as the product protocol; monitor marrow, renal function, infection, mucositis, rash, fatigue and emesis.
Nivolumab with ipilimumabUse the licensed weight-based or fixed-dose intravenous combination schedule for unresectable mesothelioma under current NICE TA818 criteria, followed to the protocol duration or stop point.Dual checkpoint blockade increases immune lung, bowel, liver, endocrine, skin, cardiac, renal and neurological toxicity; review autoimmunity, transplant, infection and steroid requirements and provide urgent contact education.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG161 pleural mesotheliomaExposure history, CT, tissue diagnosis, fluid, systemic and supportive care.
  • NICE TA818 nivolumab with ipilimumabCurrent first-line immunotherapy eligibility for unresectable mesothelioma.
  • HSE why asbestos is dangerousUK occupational exposure, latency and asbestos-related disease context.
  • BNF pemetrexedUK dose, supplementation, contraindications and monitoring.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom